Eyeworld Daily News

2018 WOC Barcelona Daily Monday

EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news

Issue link: http://daily.eyeworld.org/i/996542

Contents of this Issue

Navigation

Page 1 of 16

EyeWorld Daily News • The official 2018 WOC Barcelona Show Daily Monday, June 18, 2018 digital.eyeworld.org Paper session continues to bring the latest research to attendees by Liz Hillman EyeWorld Senior Staff Writer continued on page 3 Free paper session provides updates on late-breaking news by Liz Hillman EyeWorld Senior Staff Writer continued on page 3 A ttendees of a free paper session Sunday morning were caught up on some of the most recent news in the world of ophthal- mic research. Several studies focused on differ- ent possible treatments for dry eye disease. Anne-Marie Bleau, PhD, Madrid, Spain, described a new class of RNA interferon (RNAi) drugs that could use a natural pathway to block several of the symptoms associated with dry eye. RNAi drugs, Dr. Bleau explained, act upstream of tradition- al medications, are long-lasting, very specific, and have few side effects. Tivanisiran (Sylentis, Madrid, Spain), according to Dr. Bleau, inhibits the transient receptor potential cation channel subfam- ily V member 1 (TRPV1) protein synthesis, which she explained is an "important mediator of ocular pain signal." She said it is thought that topical Tivanisiran could reduce ocular pain and proinflammato- ry mediators and could modulate production of mucin protein to improve tear quality. Phase 1 studies showed systemic and ocular toler- ance in healthy volunteers. Two Phase 2 studies compared different doses (0.75% and 1.125%) with pla- cebo. Overall, 1.125% was effective in significantly decreasing visual analogue scale measurements, im- proving hyperemia (50% of treated eyes), improving corneal staining as measured by the Oxford Scale by at least 2 degrees, and significantly in- creasing tear breakup time (TBUT). The lower dosage also improved TBUT and conjunctival hyperemia. T he second part of the late breaking news paper sessions Sunday morning informed patients about many different topics in ophthalmic research. Ivana Kim, MD, Boston, Mas- sachusetts, U.S., introduced light-ac- tivated AU-011 (Aura Biosciences, Cambridge, Massachusetts, U.S.) as photosensitive intravitreal injection that is then activated through laser application to treat ocular melano- mas. Human trials for this treatment are underway. Viral nanoparticles are injected into the vitreous and bind to the surface of tumor cells in the choroid, Dr. Kim explained. An ophthalmic laser at 689 nm then activates the drug, which disrupts the tumor cell membrane and leads to cell death. The Phase 1b/2 open label study, which has to date enrolled 20 patients with choroidal melanoma and is evaluating the safety and efficacy of different drug dosages, number of weekly treatments, and number of laser administrations, has found no serious adverse events related to the treatment. Patients' baseline vision was preserved in all patients followed to at least 6 months, even in those with juxta-fo- veal tumors and tumors touching the optic disk, Dr. Kim said. There was mild anterior chamber inflam- mation but that resolved over time. Reduced tumor thickness was seen in the first multiple dose cohort, Dr. Kim added, and a stable tumor response with vision preser- Joobin Hooshmand, MD Ivana Kim, MD vation up to 12 months was seen in the single treatment cohorts. "We are very excited about fol- lowing the results of this treatment even further," Dr. Kim said. Other research presented by Seyedeh Maryam Hosseini, MD, Mashhad, Iran, described the potential for crocin supplements (a compound found in Crocus sativus, or saffron) as a possible additive treatment and preventative therapy for diabetic retinopathy. Saffron is known to have analgesic, anti-in- flammatory, and antioxidant proper- ties, Dr. Hosseini said, adding that it also has the potential for neuropro- tection and increasing blood flow to the retina. She described a randomized,

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld Daily News - 2018 WOC Barcelona Daily Monday